Ascent Pharmaceuticals
United States 140 employees Updated 9 July 2026
Ascent Pharmaceuticals is a finished-dose manufacturer based in United States. It appears in 13 regulatory filings across 1 regulator, without an active US DMF or CEP on file. Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 9 August 2024 as VAI.
1
registered plants
1 with an FDA FEI number
13
filings
across 1 regulators
These figures were checked against the regulators' own files on 25 July 2026
Inspections
8 of 8 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.
Inspection history
- 9 August 2024 VAI US FDA
- 15 September 2022 VAI US FDA
- 13 October 2020 VAI US FDA
- 7 November 2018 NAI US FDA
- 27 July 2018 NAI US FDA
- 21 February 2018 NAI US FDA
- 9 November 2015 VAI US FDA
- 26 September 2013 VAI US FDA
NAI means no action indicated, VAI means voluntary action indicated, and OAI means
official action indicated.
Registered plants
| Site | FDA FEI |
| Central Islip, United States | 3009518416 |
Filings and GMP by regulator
| Regulator | Filings | GMP certificates |
| US FDA | 13 | 1 |
Comparing suppliers?
Choose your molecules and target markets. Ascent Pharmaceuticals comes back tiered against every other
supplier able to file there.
Start for free No sales call.
Open risk flags
- The most recent inspection outcome was VAI, on 9 August 2024.
Sources on this page
- FDA
- Drug master files, establishment registration, inspection classifications
- EDQM
- Certificates of suitability
- EudraGMDP and national regulators
- GMP certificates